High level of galectin-1 expression is a negative prognostic predictor of recurrence in laryngeal squamous cell carcinomas

International Journal of Oncology

Volumn 30, Issue 5, 2007, Pages 1109-1117

  Saussez, Sven ^a   Decaestecker, Christine ^b   Lorfevre, Francois ^a   Cucu, Diana Raluca ^a   Mortuaire, Goeffrey ^c   Chevalier, Dominique ^c   Wacreniez, Agnes ^c   Kaltner, Herbert ^d   André, Sabine ^d   Toubeau, Gérard ^a   Camby, Isabelle ^b,e   Gabius, Hans Joachim ^d   Kiss, Robert ^b  

^a UNIVERSITY OF MONS   (Belgium)

^b UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF MUNICH   (Germany)

^e XpeDoc Sprl   (Belgium)

Author keywords

Apoptosis; Galectin; Laryngeal cancer; Recurrence; T cell death

Indexed keywords

GALECTIN 1;

ADULT; AGED; ARTICLE; BIOSYNTHESIS; FEMALE; GENE EXPRESSION REGULATION; HUMAN; LARYNX TUMOR; LYMPHOCYTE; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; RECURRENT DISEASE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; FEMALE; GALECTIN 1; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LARYNGEAL NEOPLASMS; LYMPHOCYTES; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES;

EID: 34447308820     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.5.1109     Document Type: Article

References (38)

1. Licitra L, Bernier J, Grandi C, et al: Cancer of the larynx. Crit Rev Oncol Hematol 47: 65-80, 2003.
2. Almadori G, Bussu F, Cadoni G, Galli J, Paludetti G and Maurizi M: Molecular markers in laryngeal squamous cell carcinoma: towards an integrated clinicobiological approach. Eur J Cancer 41: 683-693, 2005.
3. Ha PK and Califano JA III: The molecular biology of laryngeal cancer. Otolaryngol Clin North Am 35: 993-1012, 2002.
4. Gabius H-J: Animal lectins. Eur J Biochem 243: 543-576, 1997.
5. Gabius H-J, Siebert H-C, André S, Jiménez-Barbero J and Rüdiger H: Chemical biology of the sugar code. Chem Biol Chem 5: 740-764, 2004.
6. Villalobo A, Nogales-González A and Gabius HJ: A guide to signalling pathways connecting protein-glycan interaction with the emerging versatile effector functionality of mammalian lectins. Trends Glycosci Glycotechnol 18: 1-37, 2006. (Pubitemid 43723385)
7. Choufani G, Nagy N, Saussez S, et al: The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 86: 2353-2363, 1999.
8. Delorge S, Saussez S, Pelc K, et al: Correlation of galectin-3/galectin- 3-binding sites with low differentiation status in head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg 122: 834-841, 2000.
9. Paleri V, Pearson JP, Bulmer D, Jeannon JP, Wight RG and Wilson JA: Expression of mucin gene products in laryngeal squamous cancer. Otolaryngol Head Neck Surg 131: 84-88, 2004.
10. Danguy A, Camby I and Kiss R: Galectins and cancer. Biochim Biophys Acta 1572: 285-293, 2002.
11. Lahm H, André S, Hoeflich A, et al: Tumor galectinology: insights into a complex network of a family of endogenous lectins. Glycoconj J 20: 227-238, 2004.
12. Liu FT and Rabinovich GA: Galectins as modulators of tumour progression. Nat Rev Cancer 5: 29-41, 2005.
13. Piantelli M, Iacobelli S, Almadori G, et al: Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol 20: 3850-3856, 2002.
14. Plzak J, Betka J, Smetana K Jr, et al: Galectin-3 - an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer 40: 2324-2330, 2004.
15. Danguy A, Rorive S, Decaestecker C, et al: Immunohistochemical profile of galectin-8 expression in benign and malignant tumors of epithelial, mesenchymatous and adipous origins, and of the nervous system. Histol Histopathol 16: 861-868, 2001.
16. Saussez S, Cucu DR, Decaestecker C, et al: Galectin-7 (p53-induced gene-1): a new prognostic predictor of recurrence and survival in stage IV hypopharyngeal cancer. Ann Surg Oncol 13: 999-1009, 2006.
17. Saussez S and Kiss R: Galectin-7. Cell Mol Life Sci 63: 686-697, 2006.
18. Le QT, Shi G, Cao H, et al: Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 23: 1-10, 2005.
19. Rubinstein N, Alvarez M, Zwirner NW, et al: Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection: a potential mechanism of tumor-immune privilege. Cancer Cell 5: 241-251, 2004.
20. Camby I, Le Mercier M, Lefranc F and Kiss R: Galectin-1: A small protein with major functions. Glycobiology 16: 137-157, 2006. (Pubitemid 44530693)
21. Hyams VJ, Batsakis JG and Michaels L (eds): Tumors of the upper respiratory tract and ear. In: Atlas of Tumor Pathology. Armed Forces Institute of Pathology, Washington DC, 1988.
22. Decaestecker C, Camby I, Remmelink M, et al: Decision tree induction: a useful tool for assisted diagnosis and prognosis in tumor pathology. Lab Invest 76: 799-808, 1997.
23. Young MR: Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck. Cancer Immunol Immunother 53: 375-382, 2004. (Pubitemid 38657250)
24. Strome SE and Chen L: Costimulation-based immunotherapy for head and neck cancer. Curr Treat Opt Oncol 5: 27-33, 2004. (Pubitemid 38906622)
25. Ferris RL, Hunt JL and Ferrone S: Human leukocyte antigen (HLA) class I defects in head and neck cancer: molecular mechanisms and clinical significance. Immunol Res 33: 113-133, 2005.
26. Albers A, Abe K, Hunt J, et al: Antitumor activity of human papillomavirus type 16 E7-specific T-cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 65: 11146-11155, 2005.
27. Lopez-Albaitero A, Nayak JV, Ogino T, et al: Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176: 3402-3409, 2006.
28. Hathaway B, Landsittel DP, Gooding W, et al: Multiplexed analysis of serum cytokines as biomarkers in squamous cell carcinoma of the head and neck patients. Laryngoscope 115: 522-527, 2005.
29. Whiteside TL: Immunobiology of head and neck cancer. Cancer Metast Rev 24: 95-105, 2005.
30. Ferris RL: Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? ORL J Otorinolaryngol Relat Spec 66: 332-340, 2004.
31. Choi P and Chen C: Genetic expression profiles and biologic pathway alterations in head and neck squamous cell carcinoma. Cancer 104: 1113-1128, 2005. (Pubitemid 41278946)
32. Reichert TE, Rabinowich H, Johnson JT and Whiteside TL: Mechanisms responsible for signaling and functional defects. J Immunother 21: 295-306, 1998.
33. Dasgupta S, Bhattacharya-Chatterjee M, O'Malley BW Jr and Chatterjee SK: Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma. Mol Ther 13: 183-193, 2006.
34. Levi G, Tarrab-Hazdai R and Teichberg VI: Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits. Eur J Immunol 13: 500-507, 1983.
35. Goldstone SD and Lavin MF: Isolation of a cDNA clone, encoding a human β-galactoside-binding protein, overexpressed during glucocorticoid-induced cell death. Biochem Biophys Res Commun 178: 746-750, 1991.
36. Yang RY, Hsu DK and Liu FT: Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 93: 6737-6742, 1996.
37. Zubieta MR, Furman D, Barrio M, Bravo AI, Domenichini E and Mordoh J: Galectin-3 expression correlates with apoptosis of tumor-associated lymphocytes in human melanoma biopsies. Am J Pathol 168: 1666-1675, 2006.
38. He J and Baum L: Presentation of galectin-1 by extracellular matrix triggers T-cell death. J Biol Chem 279: 4705-4712, 2004.